## Mississippi

### Newborn Genetic Testing & Surveillance System

<table>
<thead>
<tr>
<th>State</th>
<th>Statute/Rule</th>
<th>Language Specific to Genetic Testing and Surveillance System</th>
<th>Exemption</th>
<th>Research Authority</th>
<th>Consent Required?</th>
<th>Dissent Allowed?</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>STATUTE: Title 41, Chapter 21 RULE: Title 15, Part IV, Subpart 01, Chapter 38</td>
<td>§ 41-21-201. <strong>Newborn screening program.</strong> (1) The State Department of Health shall establish, maintain and carry out a comprehensive newborn screening program designed to detect hypothyroidism, phenylketonuria (PKU), hemoglobinopathy, congenital adrenal hyperplasia (CAH), galactosemia, and such other conditions as specified by the State Board of Health and as recommended by the American Academy of Pediatrics. The State Board of Health shall adopt any rules and regulations necessary to accomplish the program. (2) The State Board of Health shall determine and specify the conditions that will be included in the comprehensive newborn screening program in addition to those conditions named in subsection (1) of this section, upon the advice and recommendations of a genetics advisory committee and in accordance with the recommendations of the American Academy of Pediatrics.</td>
<td>§ 41-21-203 Testing of newborn children for certain conditions. (1): All newborn infants shall be screened… However, no such tests shall be given to any child whose parents object thereto on the grounds that the test conflicts with his religious practices or tenets.</td>
<td>Chapter 38, Section IV…41 Laboratory Requirements: 41.07 Record Retention: Records of standardization, quality control, and patient values must be kept for at least two years. It is advisable for laboratories to retain these records until the statute of limitations regarding</td>
<td>NO</td>
<td>YES</td>
</tr>
</tbody>
</table>
Pediatrics. The advisory committee shall be appointed by the Executive Director of the State Department of Health, and shall include at least two (2) pediatricians and one (1) consumer representative from a family that has experience with a newborn infant with an abnormal screening test. The State Department of Health shall maintain a list of each of the conditions included in the comprehensive newborn screening program, which shall be made available to physicians and other health care providers who are required to provide for newborn screening testing under Section 41-21-203.

(3) The State Department of Health shall develop information materials about newborn screening tests that are available, which may be used by physicians and other health care providers to inform pregnant women and parents.

§ 41-21-203. Testing of newborn children for certain conditions.
(1) All newborn infants shall be screened by the physician or other health care provider attending the infant, using tests that have been approved by the State Board of Health, to detect those conditions listed in Section 41-21-201 and

medical malpractice actions expires as stipulated by Mississippi state law.

41.08 Specimen Retention: Specimen must be retained for at least 365 days. Under no circumstances will the retained specimen be used for research or purposes other than confirmation of previous test results.

[emphasis added]
the other conditions specified by the State Board of Health for the comprehensive newborn screening program….The tests provided under the comprehensive newborn screening program shall be evaluated in laboratories located in the United States. The State Department of Health shall follow up all positive tests with the attending physician or other health care provider who notified the department thereof, and with the parents of the newborn child. The services and facilities of the State Department of Health and those of other state boards, departments and agencies cooperating with the State Department of Health in carrying out the comprehensive newborn screening program shall be made available to all newborn infants with abnormal screening tests.

(2) The State Department of Health shall provide ongoing epidemiologic surveillance of the comprehensive newborn screening program to determine the efficacy and cost effectiveness of screening newborn infants.